首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1572430

兽用狂犬病疫苗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Veterinary Rabies Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 219 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球兽用狂犬病疫苗市场价值为5.025 亿美元，预计2024 年至2032 年复合年增长率为4.2%，原因是动物狂犬病患病率不断上升，以及人们对其人畜共患病影响的认识不断增强。

全球宠物拥有量的激增进一步推动了市场的发展，因为主人越来越认识到为宠物接种狂犬病疫苗的重要性。发展中国家的都市化和畜牧业的成长也推动了对狂犬病疫苗的需求，并将其纳入更广泛的动物健康管理策略。此外，政府支持的倡议，特别是大规模疫苗接种运动，将在可预见的未来促进市场的成长。

狂犬病发生率的上升是主要的市场驱动力。世界动物卫生组织 (WOAH) 的数据突显了狂犬病的严重性：每年约有 59,000 人因狂犬病死亡，其中 99% 是由狗咬伤造成的。这种病毒威胁主要针对哺乳动物，包括狗和猫等常见的家养宠物，症状出现后死亡率几乎达 100%。这些可怕的统计数据激发了全球对抗狂犬病的努力，最终导致了广泛的疫苗接种活动。

全球兽用狂犬病疫苗产业根据动物类型、应用、最终用途、给药途径和地区进行分类。

市场依动物类型分为伴侣动物、牲畜和野生动物。伴侣细分市场进一步分为狗、猫等，2023 年的估值为2.646 亿美元，引领市场。一需求。鑑于狗和猫是人类主要的狂犬病宿主，它们的疫苗接种对于公共卫生至关重要。此外，许多国家强制要求宠物接种狂犬病疫苗的法规凸显了伴侣细分市场的市场主导地位。

从应用角度来看，市场分为暴露前预防和暴露后预防。 2023 年，暴露后细分市场占据主导地位，占 69.7% 的份额。兽用 PEP 疫苗在保护动物（尤其是宠物和牲畜）免受因与受感染实体接触而感染狂犬病方面发挥着至关重要的作用。狂犬病症状出现后几乎肯定会死亡，这放大了市场上 PEP 的需求和重要性。

北美兽用狂犬病疫苗产业估值为1.976亿美元。预测显示，从 2024 年到 2032 年，复合年增长率为 3.8%。此外，主要製药公司的存在及其积极的研发工作进一步加强了市场的主导地位。野生动物中狂犬病的高盛行率和强有力的公共卫生倡议相结合，凸显了北美对兽用狂犬病疫苗的需求，从而巩固了该地区作为全球领导者的地位。

产业生态系统分析
产业影响力
- 成长动力
  - 狂犬病发生率上升
  - 全球宠物拥有量不断增加
  - 有利的政府法规和政策
  - 提高对狂犬病及其预防的认识
- 产业陷阱与挑战
  - 狂犬病疫苗成本高
  - 缺乏意识
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按动物类型，2021 - 2032

主要趋势
伴侣动物
- 狗
- 猫
- 其他伴侣动物
畜牧动物
- 牛
- 绵羊和山羊
- 其他家畜动物
野生动物

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
暴露前预防
暴露后预防

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
可注射

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
兽医医院和诊所
动物收容所和救援组织
科学研究机构

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Biogenesis Bago S.A.
Bioveta, a.s.
Boehringer Ingelheim International GmbH
Ceva Sante Animale S.A.
Dyntec
Elanco Animal Health Incorporated
Indian Immunologicals Limited
Merck and Co., Inc.
Vaxxinova International B.V.
Virbac S.A.
Zoetis Inc.

简介目录

Product Code: 10816

The Global Veterinary Rabies Vaccines Market was valued at USD 502.5 million in 2023 and is projected to grow at 4.2% CAGR from 2024 to 2032, attributed to the rising prevalence of rabies in animals and the growing awareness of its zoonotic implications.

The global surge in pet ownership has further propelled the market, as owners increasingly recognize the importance of vaccinating their pets against rabies. Urbanization and the growth of livestock farming in developing nations are also driving the demand for rabies vaccines, integrated into broader animal health management strategies. Additionally, government-backed initiatives, especially mass vaccination campaigns, are set to bolster the market's growth in the foreseeable future.

The rising incidence of rabies serves as a primary market driver. Data from the World Organization of Animal Health (WOAH) highlights the severity: rabies accounts for roughly 59,000 annual fatalities, with a staggering 99% stemming from dog bites. This viral menace predominantly targets mammals, including common domestic pets like dogs and cats, and boasts an almost 100% fatality rate post-symptom onset. Such dire statistics have galvanized global efforts to combat rabies, culminating in extensive vaccination drives.

The global veterinary rabies vaccines industry is classified based on animal type, application, end-use, route of administration and region.

The market categorizes based on animal type into companion animals, livestock, and wildlife. The companion segment, further divided into dogs, cats, and others, led the market with a valuation of USD 264.6 million in 2023. Heightened awareness among pet owners about rabies vaccination's significance, combined with a global uptick in pet ownership, has driven this demand. Given that dogs and cats are primary rabies reservoirs for humans, their vaccination becomes paramount for public health. Furthermore, many countries' regulations mandating pet rabies vaccinations underscore the companion segment's market dominance.

Application-wise, the market divides into pre-exposure and post-exposure prophylaxis. The post-exposure segment led with a commanding 69.7% share in 2023. Its dominance stems from its pivotal role in thwarting rabies onset after potential exposure. Veterinary PEP vaccines play a crucial role in protecting animals, especially pets and livestock, from rabies through contact with infected entities. The near-certain fatality of rabies post-symptom emergence amplifies the demand and significance of PEP in the market.

North America Veterinary Rabies Vaccines Industry was valued at USD 197.6 million. Projections indicate a growth at a CAGR of 3.8% from 2024 to 2032. The region is characterized by a strong veterinary healthcare infrastructure, an increase in awareness among pet owners, and strict government regulations that mandate rabies vaccinations for pets. Additionally, the market's dominance is further strengthened by the presence of major pharmaceutical companies and their active research and development efforts. The combination of a high prevalence of rabies in wildlife and strong public health initiatives highlights the demand for veterinary rabies vaccines in North America, reinforcing the region's position as a global leader.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of rabies
  - 3.2.1.2 Rising pet ownership globally
  - 3.2.1.3 Favorable government regulations and policies
  - 3.2.1.4 Increased awareness about rabies and its prevention
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of rabies vaccines
  - 3.2.2.2 Lack of awareness
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Companion animals
- 5.2.1 Dogs
- 5.2.2 Cats
- 5.2.3 Other companion animals
5.3 Livestock animals
- 5.3.1 Cattle
- 5.3.2 Sheep and goats
- 5.3.3 Other livestock animals
5.4 Wildlife

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Pre exposure prophylaxis
6.3 Post exposure prophylaxis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary hospitals and clinics
8.3 Animal shelters and rescue organizations
8.4 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa